

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (canceled)
4. (canceled)
5. (canceled)
7. (canceled)
8. (canceled)
9. (canceled)
10. (canceled)
11. (canceled)
12. (canceled)
26. (Canceled)
29. (Canceled)
30. (canceled)
32. (canceled)
34. (canceled)
35. (canceled)
36. (canceled)

37. (currently amended) A pharmaceutical or cosmetic composition comprising:

(a) an ~~a solid-free~~ oleaginous pharmaceutical or cosmetic carrier containing, by weight, 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, ~~and~~

~~(b) a therapeutically or cosmetically effective amount of a biologically active substance;~~

wherein said solidifying agent is selected from the group consisting of at least one long chain fatty acid, having at least 15 carbon atoms in its carbon backbone and at least one fatty acid, having at least 18 carbons in its carbon backbone and further wherein said solidifying agent includes a substance selected such that under ambient conditions, the carrier is semi-solid at rest and liquefies upon application of shear forces thereto; and

(b) a therapeutically or cosmetically effective amount of a biologically active substance,

wherein the composition is free of particulate material that prevents liquification of the carrier upon application of shear force.

40. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said hydrophobic solvent is selected from the group consisting of at least one marine animal derived oil, at least one terrestrial animal derived oil, at least one mineral oil, at least one silicone oil and at least one plant-derived oil.

41. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said hydrophobic solvent includes an oil selected from the group consisting of olive oil, soybean oil, canola oil, rapeseed oil, cottonseed oil, coconut oil, palm oil, sesame oil, sunflower oil, safflower oil, rice bran oil, borage seed oil, syzigium aromaticum oil, hempseed oil, herring oil, cod-liver oil, salmon oil, corn oil, flaxseed oil, wheat germ oil, rape seed oil, evening

primrose oil, rosehip oil, tea tree oil, melaleuca oil and jojoba oil.

43. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said solidifying agent has at least one alkyl group side chain in its carbon backbone.

44. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at position α and β .

45. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said carbon backbone of said fatty alcohol has at least one hydroxyl group at position α and β .

46. (previously presented) The pharmaceutical or cosmetic composition claim 37, wherein said carbon backbone of said fatty acid or said fatty alcohol has at least one hydroxyl group at positions 8-14.

47. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said solidifying agent includes a 12-hydroxy fatty acid.

48. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein at least one of said solidifying agent and said hydrophobic solvent has a therapeutic or cosmetic beneficial effect.

49. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said biologically active substance is selected from the group of consisting of an antibiotic agent, a free radical generating agent, an antifungal agent, an antiviral agent, a non-nucleoside reverse transcriptase inhibitor, a nucleoside-analog reverse transcriptase inhibitor, a

protease inhibitor, a non-steroidal anti-inflammatory drug, an immunosuppressant, an antihistamine agent, an anti-inflammatory agent, a retinoid agent, a tar agent, an antipruritics agent and a scabicide agent.

50. (previously presented) The pharmaceutical or cosmetic composition of claim 49, wherein:

(a) said antibiotic agent is selected from the group consisting of chloramphenicol, tetracyclines, synthetic and semi-synthetic penicillins, beta-lactams, quinolones, fluoroquinolones, macrolide antibiotics, peptide antibiotics, cyclosporines, erythromycin and clindamycin;

(b) said free radical generating agent is benzoyl peroxide;

(c) said antifungal agent is selected from the group consisting of azoles, diazoles, triazoles, miconazole, fluconazole, ketoconazole, clotrimazole, itraconazole, griseofulvin, ciclopirox, amorolfine, terbinafine, Amphotericin B and potassium iodide;

(d) said antiviral agent is selected from the group consisting of flucytosine (5FC), Vidarabine, acyclovir and Gancyclovir;

(e) said nucleoside-analog reverse transcriptase inhibitor is selected from the group consisting of Zidovudine, Stavudine and Lamivudine;

(f) said non-nucleoside reverse transcriptase inhibitor is selected from the group consisting of Nevirapine and Delavirdine;

(g) said protease inhibitor is selected from the group consisting of Saquinavir, Ritonavir, Indinavir, Nelfinavir, Ribavirin, Amantadine, Rimantadine and Interferon;

(h) said immunosuppressant is selected from the group consisting of Clobetasol propionate, Halobetasol propionate, Betamethasone dipropionate, Betamethasone valerate, Fluocinolone acetonide, Halcinonide, Betamethasone valerate, Fluocinolone acetonide, Hydrocortisone valerate, Triamcinolone acetonide, Hydrocortisone and hexachlorobenzene;

(i) said anti-inflammatory agent is a vitamin B3 or a derivative thereof;

(j) said retinoid agent is selected from the group consisting of isotretinoin, adapalene and tretinoin;

(k) said tar agent is selected from the group consisting of coal tar and cade oil;

(l) said antihistamine agent is doxepine hydrochloride;

(m) said antipruritic agent is crotampiton; and

(n) said scabicide agent is selected from the group consisting of benzyl benzoate, malathion and crotamiton.

51. (previously presented) The pharmaceutical or cosmetic composition of claim 37, wherein said biologically active substance is effective in the treatment of a disease or disorder selected from the group consisting of psoriasis, acne, seborrhea, seborrheic dermatitis, alopecia and excessive hair growth, ichthyosis, wounds, burns, cuts, ulcers, psoriasis, seborrheic dermatitis of the face and trunk, seborrheic blepharitis, contact dermatitis, stasis dermatitis and exfoliative dermatitis.

104 52. (new) The pharmaceutical or cosmetic composition of claim 37, wherein the carrier comprises, by weight, 4-12 percent of a solidifying agent and 88-96 percent of a hydrophobic solvent.

Rule
1.126
MMP

PATENTS

Attorney Docket No. 113873-120US2

Rule
1.126
mg
105
~~53.~~ (new) The pharmaceutical or cosmetic composition of claim 52, wherein the carrier comprises, by weight, 5-10 percent of a solidifying agent.